Managed Care
Disease
Management

Using Antiplatelet Agents To Lower Risk of Stroke and MI

Using Antiplatelet Agents To Lower Risk of Stroke and MI

Atherosclerosis is a contributing factor to heart attack, stroke, or peripheral arterial disease. These overlapping disease states are linked by common risk factors and a shared pathophysiologic factor, the platelet. Antiplatelet therapy, therefore, may help to reduce the risk of vascular events and thereby lessen the morbidity, mortality, and cost associated with atherosclerosis and its consequences. The material in this publication stems from a panel discussion of experts in neurology, cardiovascular medicine, and vascular medicine, along with representatives of leading MCOs. Their goal was to reach a consensus on use of antiplatelet therapy within a managed care environment. Clinical pathways for therapy related to myocardial infarction, stroke, and peripheral arterial disease were developed by consensus of the panel and are presented herein. Lawrence M. Brass, MD, of Yale University and Randall Zusman, MD, of Harvard University co-chaired the meeting.

Highlights:

  • Clinical and Economic Implications of Atherosclerosis
  • Antiplatelet Therapy: A Perspective From Cardiology
  • Antiplatelet Therapy: A Perspective From Vascular Medicine
  • Antiplatelet Therapy: A Perspective From Neurology

Meetings

HealthIMPACT Southeast Tampa, FL January 23, 2015